[
  {
    "name": "Craif",
    "description": "Urine-based miRNA test, 7 cancer types",
    "raised": "$22M",
    "status": "Revenue in Japan",
    "threat": "medium",
    "difference": "Requires urine sample. We need no sample at all.",
    "updated": "Apr 2025"
  },
  {
    "name": "Galleri (GRAIL)",
    "description": "Multi-cancer liquid biopsy, blood-based",
    "raised": "$1.9B+",
    "status": "Commercial ($950/test)",
    "threat": "medium",
    "difference": "Needs 50-100M cells. Only 17% Stage I sensitivity. We detect at 5-10M cells.",
    "updated": "2025"
  },
  {
    "name": "Michigan State SERS",
    "description": "Raman nanoparticle cancer detection",
    "raised": "Academic",
    "status": "Research phase",
    "threat": "low",
    "difference": "Requires nanoparticles applied to tissue. Not non-invasive.",
    "updated": "Dec 2025"
  },
  {
    "name": "SpotitEarly",
    "description": "Trained dogs + AI cancer detection",
    "raised": "Unknown",
    "status": "Clinical partnership (Hackensack Meridian)",
    "threat": "low",
    "difference": "Not scalable. We're a device, not a dog.",
    "updated": "Oct 2025"
  },
  {
    "name": "DermaSensor",
    "description": "Handheld skin lesion scanner, FDA cleared",
    "raised": "$30M+",
    "status": "FDA cleared, commercial",
    "threat": "medium",
    "difference": "Detects visible lesions only. We detect pre-lesion. Different stage entirely.",
    "updated": "2024"
  },
  {
    "name": "Surfix Diagnostics",
    "description": "Photonic chip liquid biopsy",
    "raised": "Seed",
    "status": "Pre-clinical",
    "threat": "low",
    "difference": "Still blood-based. Photonics but requires sample.",
    "updated": "2025"
  }
]
